Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Aged
Antigens, Surface
/ metabolism
Castration
/ statistics & numerical data
Glutamate Carboxypeptidase II
/ metabolism
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ pathology
Organs at Risk
/ radiation effects
Prognosis
Prospective Studies
Prostatic Neoplasms
/ pathology
Radiosurgery
/ methods
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ methods
Radiotherapy, Intensity-Modulated
/ methods
Re-Irradiation
/ methods
Salvage Therapy
Survival Rate
Castrate resistant
Prostate
Re-irradiation
Salvage
Stereotactic body radiation therapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
23 Jun 2021
23 Jun 2021
Historique:
received:
02
05
2021
accepted:
10
06
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
22
12
2021
Statut:
epublish
Résumé
Advances in imaging, biomaterials and precision radiotherapy provide new opportunities to salvage locally recurrent prostate cancer (PC). This study evaluates the efficacy and safety of re-irradiation using stereotactic body radiation therapy (SBRT). We hypothesized that patients with castrate-resistant PC (CRPC) would benefit less from local salvage. A prospective clinical database was reviewed to extract 30 consecutive patients treated with prostate re-irradiation. Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography was performed following prostate-specific antigen failure in all patients and biopsy was obtained in 18 patients (60%). Re-irradiation was either focal (n = 13) or whole-gland (n = 17). Endo-rectal balloons were used in twenty-two patients and hydrogel spacers in eight patients. The median prescription dose was 5 fractions of 6.5 (range: 6-8) Gray (Gy). Median follow-up was 28 months. Failure occurred in 10 (out of 11) CRPC patients versus 6 (out of 19) castrate-sensitive patients (91% vs. 32%, p = 0.008) after a median of 13 and 23 months, respectively. Metastases occurred in 64% (n = 7) of CRPC patients versus 16% (n = 3) of castrate-sensitive patients (p = 0.007). Two patients experienced local in-field recurrence, thus local control was 93%. The 2 and 3-year recurrence-free survival were 84% and 79% for castrate-sensitive patients versus 18% and 9% for CRPC patients (p < 0.001), and 3-year metastasis-free survival was 90% versus 27% (p < 0.01) for castrate-sensitive and CRPC patients, respectively. Acute grade II and III genitourinary (GU) toxicity occurred in 27% and 3%, and late GU toxicity in 30% and 3%, respectively. No ≥ grade II acute gastrointestinal (GI) toxicity occurred, and only one patient (3%) developed late grade II toxicity. Early delivery of salvage SBRT for local recurrence is associated with excellent 3-year disease control and acceptable toxicity in the castrate-sensitive phenotype. PSMA imaging for detection of local recurrence and the use of precision radiotherapy with rectal protective devices should be further investigated as a novel salvage strategy for radio-recurrent PC.
Sections du résumé
BACKGROUND
BACKGROUND
Advances in imaging, biomaterials and precision radiotherapy provide new opportunities to salvage locally recurrent prostate cancer (PC). This study evaluates the efficacy and safety of re-irradiation using stereotactic body radiation therapy (SBRT). We hypothesized that patients with castrate-resistant PC (CRPC) would benefit less from local salvage.
METHODS
METHODS
A prospective clinical database was reviewed to extract 30 consecutive patients treated with prostate re-irradiation. Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography was performed following prostate-specific antigen failure in all patients and biopsy was obtained in 18 patients (60%). Re-irradiation was either focal (n = 13) or whole-gland (n = 17). Endo-rectal balloons were used in twenty-two patients and hydrogel spacers in eight patients. The median prescription dose was 5 fractions of 6.5 (range: 6-8) Gray (Gy).
RESULTS
RESULTS
Median follow-up was 28 months. Failure occurred in 10 (out of 11) CRPC patients versus 6 (out of 19) castrate-sensitive patients (91% vs. 32%, p = 0.008) after a median of 13 and 23 months, respectively. Metastases occurred in 64% (n = 7) of CRPC patients versus 16% (n = 3) of castrate-sensitive patients (p = 0.007). Two patients experienced local in-field recurrence, thus local control was 93%. The 2 and 3-year recurrence-free survival were 84% and 79% for castrate-sensitive patients versus 18% and 9% for CRPC patients (p < 0.001), and 3-year metastasis-free survival was 90% versus 27% (p < 0.01) for castrate-sensitive and CRPC patients, respectively. Acute grade II and III genitourinary (GU) toxicity occurred in 27% and 3%, and late GU toxicity in 30% and 3%, respectively. No ≥ grade II acute gastrointestinal (GI) toxicity occurred, and only one patient (3%) developed late grade II toxicity.
CONCLUSIONS
CONCLUSIONS
Early delivery of salvage SBRT for local recurrence is associated with excellent 3-year disease control and acceptable toxicity in the castrate-sensitive phenotype. PSMA imaging for detection of local recurrence and the use of precision radiotherapy with rectal protective devices should be further investigated as a novel salvage strategy for radio-recurrent PC.
Identifiants
pubmed: 34162398
doi: 10.1186/s13014-021-01839-w
pii: 10.1186/s13014-021-01839-w
pmc: PMC8220691
doi:
Substances chimiques
Antigens, Surface
0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Références
BJU Int. 2016 Jan;117(1):55-61
pubmed: 25711672
Urol Oncol. 2014 Jul;32(5):701-6
pubmed: 24629499
Brachytherapy. 2014 Jan-Feb;13(1):53-8
pubmed: 24295965
Radiother Oncol. 2011 Sep;100(3):436-41
pubmed: 21963289
Urology. 2006 Sep;68(3):593-8
pubmed: 16979731
Perm J. 2019;23:
pubmed: 31050644
Radiother Oncol. 2003 Jun;67(3):285-94
pubmed: 12865176
Cancer. 2008 Jan 15;112(2):307-14
pubmed: 18050294
J Appl Clin Med Phys. 2017 May;18(3):37-43
pubmed: 28407345
J Urol. 2006 Nov;176(5):2025-31; discussion 2031-2
pubmed: 17070244
Cancer Commun (Lond). 2018 Apr 17;38(1):11
pubmed: 29764515
Biomed Res Int. 2014;2014:316272
pubmed: 24967355
J Urol. 2005 Apr;173(4):1156-60
pubmed: 15758726
Urol Oncol. 2019 Sep;37(9):582-598
pubmed: 31133370
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):291-299
pubmed: 31629838
Urology. 2018 May;115:39-44
pubmed: 29174940
Brachytherapy. 2017 Mar - Apr;16(2):291-298
pubmed: 28139422
J Urol. 2015 Dec;194(6):1624-30
pubmed: 26165583
J Urol. 2007 Oct;178(4 Pt 1):1253-7; discussion 1257
pubmed: 17698104
Eur Urol Focus. 2016 Jun;2(2):158-171
pubmed: 28723532
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):727-734
pubmed: 31344433
Lancet Oncol. 2016 Jun;17(6):747-756
pubmed: 27160475
Radiat Oncol. 2012 Dec 10;7:209
pubmed: 23227960
Eur Urol. 2011 Aug;60(2):205-10
pubmed: 21420229
J Nucl Med. 2019 Jun;60(6):786-793
pubmed: 30530831
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985
pubmed: 28209443
Transl Androl Urol. 2015 Jun;4(3):365-80
pubmed: 26814148
Brachytherapy. 2014 Mar-Apr;13(2):111-6
pubmed: 24373762
Semin Radiat Oncol. 2017 Jan;27(1):67-78
pubmed: 27986213
Prostate Cancer Prostatic Dis. 2019 May;22(2):309-316
pubmed: 30385835
Pharmacotherapy. 2018 Oct;38(10):999-1009
pubmed: 30080934
Radiat Oncol. 2017 Jun 9;12(1):95
pubmed: 28599663
AJR Am J Roentgenol. 2015 Oct;205(4):807-16
pubmed: 26397329
Expert Rev Anticancer Ther. 2020 Nov;20(11):947-956
pubmed: 32909471
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343
pubmed: 30312717
Prostate. 2019 Sep;79(13):1514-1522
pubmed: 31421657
BJU Int. 2012 Dec;110(11 Pt B):E647-52
pubmed: 22788857
Transl Androl Urol. 2019 Dec;8(Suppl 5):S538-S541
pubmed: 32042641
Urology. 2003 Jul;62(1):86-91; discussion 91-2
pubmed: 12837428
Eur Urol. 2003 Jan;43(1):12-27
pubmed: 12507539
J Cancer Res Clin Oncol. 2020 Sep;146(9):2311-2317
pubmed: 32583236
J Appl Clin Med Phys. 2002 Winter;3(1):6-11
pubmed: 11817999
Int Braz J Urol. 2018 May-Jun;44(3):435-439
pubmed: 29792652